Your browser doesn't support javascript.
loading
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.
Cooper, Daniel H; Ramachandra, Ranuk; Ceban, Felicia; Di Vincenzo, Joshua D; Rhee, Taeho Greg; Mansur, Rodrigo B; Teopiz, Kayla M; Gill, Hartej; Ho, Roger; Cao, Bing; Lui, Leanna M W; Jawad, Muhammad Youshay; Arsenault, Juliet; Le, Gia Han; Ramachandra, Diluk; Guo, Ziji; McIntyre, Roger S.
Afiliación
  • Cooper DH; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. Electronic address: 18dhc2@queensu.ca.
  • Ramachandra R; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: ranuk.ramachandra@mail.utoronto.ca.
  • Ceban F; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: felicia.ceban@mail.utoronto.ca.
  • Di Vincenzo JD; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: joshua.divincenzo@uhnresearch.ca.
  • Rhee TG; Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA; VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA; Department of Public Health Sciences, School of Medicine, University of Connectic
  • Mansur RB; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, ON, Canada. Electronic address: rodrigo.mansur@uhn.ca.
  • Teopiz KM; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: kayla.teopiz@mail.utoronto.ca.
  • Gill H; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, ON, Canada. Electronic address: hartej.gill@mail.utoronto.ca.
  • Ho R; Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore. Electronic address: pcmrhcm@nus.edu.sg.
  • Cao B; Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, 400715, PR China. Electronic address: bingcao@swu.edu.cn.
  • Lui LMW; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, ON, Canada. Electronic address: leanna.lui@mail.utoronto.ca.
  • Jawad MY; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. Electronic address: youshayjwd@gmail.com.
  • Arsenault J; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: juliet.arsenualt@mail.utoronto.ca.
  • Le GH; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: hanny.legiahan@gmail.com.
  • Ramachandra D; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. Electronic address: diluk.ramachandra@mail.utoronto.ca.
  • Guo Z; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: ziji.guo@mail.utoronto.ca.
  • McIntyre RS; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON,
J Psychiatr Res ; 164: 80-89, 2023 08.
Article en En | MEDLINE | ID: mdl-37331261
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: J Psychiatr Res Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: J Psychiatr Res Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido